Submit Manuscript  

Article Details


Comparison between Atorvastatin and Rosuvastatin on Secondary Percutaneous Coronary Intervention Rate and the Risk Factors in Patients with Coronary Heart Disease

[ Vol. 21 , Issue. 10 ]

Author(s):

Jie Zhang, Jiaqi Wang, Han Yu, Guanghua Wang, Junfang Zhang, Rui Zhu*, Xuebo Liu* and Jue Li*   Pages 818 - 828 ( 11 )

Abstract:


Background: Statins are effective for patients with decreased low-density lipoprotein therapy.

Objective: The aim is to compare atorvastatin versus rosuvastatin on secondary percutaneous coronary intervention (PCI) rate and explore risk factors in coronary heart disease (CHD) patients.

Methods: A cohort study with 283 CHD subjects was launched from 2011 to 2015. Cox proportional hazards regression model, Receiver Operating Characteristic (ROC) and nomogram were used to compare the effect of atorvastatin and rosuvastatin on secondary PCI rate and disease risk factors. Even why the two statins had different effects based on gene expression profile analysis has been explored.

Results: Gene FFA (Freely fatty acid), AST (Aspartate Transaminase) and ALT (Alanine transaminase) showed the statistical difference between the four statin groups (P<0.05). In the AA group (Continuous Atorvastatin usage), albumin was a risk factor (Hazard Ratio (HR):1.076, 95%CI (1.001, 1.162), p<0.05). In the AR group (Start with Atorvastatin usage, then change to Rosuvastatin usage), ApoA was a protective factor (HR:0.004, 95%CI (0.001, 0.665), p<0.05). GLB (Galactosidase Beta) was a risk factor (HR:1.262, 95%CI (1.010, 1.576), p<0.05). In RR group (Continuous Rosuvastatin usage), ApoE was a protective factor (HR:0.943, 95%CI (0.890, 1.000), p<0.05). ALT was a risk factor (HR:1.030, 95%CI (1.000, 1.060), p<0.05).

Conclusion: Patients in the RA group had the lowest secondary PCI rate. ALT was a risk factor in the RR group. Gene Gpt (Glutamic Pyruvic Transaminase) encoded for one subtype of ALT had a significantly different expression in different statin groups.

Keywords:

Percutaneous coronary intervention, coronary heart disease, rosuvastatin, atorvastatin, Gpt, ALT.

Affiliation:

Department of Cardiology, Shanghai Tongji Hospital Affiliated to Tongji University School of Medicine, Shanghai, 200065, Institute of Clinical Epidemiology and Evidence-based Medicine, Tongji University School of Medicine, Shanghai, 200092, Department of Cardiology, Shanghai Tongji Hospital Affiliated to Tongji University School of Medicine, Shanghai, 200065, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, 201204, Institute of Clinical Epidemiology and Evidence-based Medicine, Tongji University School of Medicine, Shanghai, 200092, Department of Cardiology, Shanghai Tongji Hospital Affiliated to Tongji University School of Medicine, Shanghai, 200065, Department of Cardiology, Shanghai Tongji Hospital Affiliated to Tongji University School of Medicine, Shanghai, 200065, Department of Cardiology, Shanghai Tongji Hospital Affiliated to Tongji University School of Medicine, Shanghai, 200065

Graphical Abstract:



Read Full-Text article